Arizona · A9570

Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose in Arizona

Arizona Medicare Avg
$3,405.54
60% above national avg
National Medicare Avg
$2,133.41
All states combined
Billed Charge (AZ)
$12,333.28
What providers submit
Est. Commercial (AZ)
$9,745.40
National avg: $5,993.66
Est. Cash / Self-Pay (AZ)
$6,597.38
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

16
Services in AZ
7
Providers
N/A
Min Payment
N/A
Max Payment

Arizona Pricing in Context

In Arizona, CPT code A9570 (Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose) carries an average Medicare payment of $3,405.54 — 60% above the national benchmark of $2,133.41. 7 providers across the state submitted claims for this procedure in 2023, performing 16 total services. Individual payments in AZ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Arizona is $12,333.28, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Arizona sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Medical Supplies procedures, the estimated commercial insurance price in Arizona lands near $9,745.40, with self-pay cash prices typically around $6,597.38. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose cost in Arizona?

The average Medicare payment for Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose in Arizona is $3,405.54, which is 60% above the national average of $2,133.41. Providers in AZ typically bill $12,333.28 for this procedure.

What does Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose cost with insurance in Arizona?

With commercial insurance in Arizona, Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose costs an estimated $9,745.40. Without insurance, the estimated cash price is $6,597.38. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose in Arizona?

7 providers in Arizona billed Medicare for Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose in 2023, performing 16 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose cheaper in Arizona than the national average?

No — Indium In-111 Labeled Autologous White Blood Cells, Diagnostic, Per Study Dose costs 60% above the national average in Arizona. The state average Medicare payment is $3,405.54 compared to $2,133.41 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial